American Journal of Ophthalmology
Volume 140, Issue 1 , Pages 1.e1-1.e8 , July 2005

The Safety and Efficacy of Travoprost 0.004%/Timolol 0.5% Fixed Combination Ophthalmic Solution

  • Howard S. Barnebey, MD

      Affiliations

    • University of Washington, Ophthalmology, Specialty Eye Care Center, Seattle, Washington
    • Corresponding Author InformationInquiries to Howard Barnebey, MD, University of Washington, Ophthalmology, Specialty Eye Care Center, Boren Avenue, Suite 1030, Seattle, WA 98004; fax: (206) 447-8164
    • ,
  • Silvia Orengo-Nania, MD

      Affiliations

    • Ophthalmology Baylor College of Medicine-Cullen Eye Institute, Houston, Texas
    • ,
  • Brian E. Flowers, MD

      Affiliations

    • Ophthalmology Associates, Fort Worth, Texas
    • ,
  • John Samples, MD

      Affiliations

    • Ophthalmology-Glaucoma Service, Casey Eye Institute-Oregon Health Science, Portland, Oregon
    • ,
  • Sushanta Mallick, PhD

      Affiliations

    • Alcon Research, Ltd., Fort Worth, Texas
    • ,
  • Theresa A. Landry, PhD

      Affiliations

    • Alcon Research, Ltd., Fort Worth, Texas
    • ,
  • Michael V.W. Bergamini, PhD

      Affiliations

    • Alcon Research, Ltd., Fort Worth, Texas

,Accepted 20 February 2005.

References 

  1. Zimmerman TJ , Kaufman HE . Timolol, a beta-adrenergic blocking agent for the treatment of glaucoma . Arch Ophthalmol . 1981;95:601–607
  2. The AGIS Investigators . The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration . Am J Ophthalmol . 2000;130:429–440
  3. LeBlanc RP , Krip G . Timolol, Canadian multi-center study . Ophthalmology . 1981;88:244–248
  4. Reiss GR , Brubaker RF . The mechanism of betaxolol, a new ocular hypotensive agent . Ophthalmology . 1983;90:1369–1372
  5. Sharif NA , Kelly CR , Crider JY . Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues . Invest Ophthalmol Vis Sci . 2003;44:715–721
  6. Sharif NA , Crider JY , Husain S , Kaddour-Djebbar I , Ansari AR , Abdel-Latif AA . Human ciliary muscle cell responses to FP-class prostaglandin analogs (phosphoinositide hydrolysis, intracellular Ca2+ mobilization and MAP kinase activation) . J Ocular Pharm Ther . 2003;19:437–455
  7. Camras CB . Mechanism of the prostaglandin-induced reduction of intraocular pressure in human . Adv Prostaglandin Thromboxane Leukot Res . 1995;23:519–525
  8. Brubaker RF , Schoff EO , Nau CB , Carpenter SP , Chen K , Vandenburgh AM . Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics . Am J Ophthalmol . 2001;131:19–24
  9. Netland PA , Landry T , Sullivan EK , et al.   Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension . Am J Ophthalmol . 2001;132:472–484
  10. Fellman RL , Sullivan EK , Ratliff M , et al.   Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure (a 6-month, masked, multicenter trial) . Ophthalmology . 2002;109:998–1008
  11. Kass MA , Heuer DK , Higginbotham EJ , et al.   The Ocular Hypertension Treatment Study (A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary-open angle glaucoma) . Arch Ophthalmol . 2002;120:701–713
  12. Weinreb RN . Compliance with medical treatment of glaucoma . J Glaucoma . 1992;1:134–136
  13. Patel SC , Spaeth GL . Compliance in patients prescribed eyedrops for glaucoma . Ophthalmic Sur . 1995;26:233–236
  14. Stewart WC , Garrison PM . Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events . Arch Intern Med . 1998;158:221–226
  15. Tsai JC , McClure CA , Ramos SE , Schlundt DG , Pichert JW . Compliance barriers in glaucoma (A systematic classification) . J Glaucoma . 2003;12:393–398
  16. Wax MB , Camras CB , Fiscell RG , Girkin C , Singh K , Weinreb RB . Emerging perpectives in glaucoma (Optimizing 24-hour control of intraocular pressure) . Am J Ophthalmol . 2002;133:S1–S10
  17. Heijl A , Leske MC , Bengtsson B , et al.   Reduction of intraocular pressure and glaucoma progression (results from the Early Manifest Glaucoma Trial) . Arch Ophthalmol . 2002;120:1268–1279
  18. Lichter PR , Musch DC , Gillespie BW , et al.   Interim clinical outcomes in the collaborative initial glaucoma treatment study comparing initial treatment randomized to medications or surgery . Ophthalmology . 2001;108:1943–1953
  19. Asrani S , Zeimer R , Wilensky J , Gieser D , Vitale S , Lindenmuth K . Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma . J Glaucoma . 2000;9:134–142
  20. Liu JHK , Kripke DF , Twa MD , et al.   Twenty-four-hour pattern of intraocular pressure in the aging population . Invest Ophthalmol Vis Sci . 1999;40:2912–2917
  21. Greenberg RN . Overveiw of patient compliance with medication dosing (a literature review) . Clin Ther . 1984;6:592–599
  22. Strohmaier K , Snyder E , DuBiner H , Adamsons I  Dorzolamide-Timolol Study Group . The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components . Ophthalmology . 1998;105:1936–1944
  23. Choudhuri S , Wand M , Shields MB . A comparison of dorzolamide-timolol combination versus the concomitant drugs . Am J Ophthalmol . 2000;130:832–833

 This study was supported by Alcon Research Ltd., Fort Worth, Texas.

PII: S0002-9394(05)00266-7

doi: 10.1016/j.ajo.2005.02.043

American Journal of Ophthalmology
Volume 140, Issue 1 , Pages 1.e1-1.e8 , July 2005

Article Tools

* Image Usage & Resolution